Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | PARG | Q86W56 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497190 | 1.00 | LMNA (0.47) | LMNAMAPTCYP3A4APEX1MAPK1 | |
| SCHEMBL1536387 | 0.84 | CYP1A2 (0.44) | LMNAMAPTCYP3A4APEX1MAPK1 | |
| SCHEMBL30960545 | 0.79 | LMNA (0.61) | LMNAMAPTCYP3A4APEX1MAPK1 | |
| SCHEMBL29228475 | 0.79 | LMNA (0.61) | LMNAMAPTCYP3A4APEX1MAPK1 | |
| SCHEMBL29786977 | 0.79 | LMNA (0.50) | LMNAMAPTCYP3A4APEX1MAPK1 | |
| SCHEMBL1317870 | 0.79 | LMNA (0.50) | LMNAMAPTCYP3A4APEX1MAPK1 | |
| SCHEMBL8404535 | 0.79 | CYP2A6 (0.57) | LMNACYP2A6CYP1A2ALDH1A1UHRF1 | |
| SCHEMBL15427882 | 0.78 | CYP3A4 (0.40) | LMNAMAPTCYP3A4APEX1MAPK1 | |
| SCHEMBL18691153 | 0.77 | LMNA (0.44) | LMNAMAPTCYP3A4APEX1MAPK1 | |
| SCHEMBL25368878 | 0.76 | MAPT (0.47) | LMNAMAPTCYP3A4APEX1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| CN-119421877-A | Substituted heterocyclic compounds as HSET inhibitors | 默克专利股份公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4463444-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-20240067669-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3921316-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021136238-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | 武汉朗来科技发展有限公司 | 2021-07-08 | — | — | WO | disclosed |
| EP-3562821-B9 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2021-05-26 | — | — | EP | disclosed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| WO-2001039759-A2 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-07 | — | — | WO | disclosed |
| EP-0944386-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| CN-1244798-A | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | RHONE POULENC RORER PHARMA (US) | 2000-02-16 | — | — | CN | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0944386-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025611-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067669-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | C1S, CHRM1, C1R | LMNA 1791/4885MAPT 4301/4885CYP3A4 148/4885 |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | LMNA 3190/4885MAPT 3266/4885CYP3A4 2807/4885 |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | ENGASE, UGGT1, MGAT3 | LMNA 2029/4885MAPT 4269/4885CYP3A4 277/4885 |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | LMNA 868/4885MAPT 4883/4885CYP3A4 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.